[U.S. Stocks Movement] Arrivent plunges on October 6: FURVENT trial fails and primary endpoints not met
Bitget异动解读2026/10/06 13:35Arrivent October 6th: Major Decline Analysis
Keywords: FURVENT trial failure, primary endpoint not achieved
On October 6, 2026, ArriVent announced that the FURVENT Phase III trial did not achieve the primary endpoint of progression-free survival as assessed by a blinded independent central review. The median progression-free survival was 11.0 months in the firmonertinib 240mg group, compared to 9.5 months in the control group. The difference was not statistically significant, with a p-value of 0.0654. The company stated it is currently evaluating subsequent development strategies.
(Disclaimer: This content was generated by AI technology by collecting and summarizing public information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot platinum hits the $1700 mark, now quoted at $1699.60, down 1.46% on the day
Spot platinum has just crossed the $1,700.00/oz mark, now quoted at $1,699.60/oz, down 1.46% on the day; Nymex platinum futures main contract is currently at $1,708.8/oz, down 0.86% on the day.
Crypto prices
More
